cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2023-3839XDJVKIcardiovascular-3839Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESПрогностическая ценность морфологических, биохимических, молекулярно-генетических маркеров фиброза у пациентов с гипертрофической кардиомиопатиейPrognostic value of morphological, biochemical, molecular markers of fibrosis in patients with hypertrophic cardiomyopathyhttps://orcid.org/0009-0009-5597-0200БурнашеваГ. А.BurnashevaG. A.

Врач-кардиолог.

Москва

Moscow

Ledebouria@mail.ruhttps://orcid.org/0000-0002-9024-5364МясниковР. П.MyasnikovR. P.

к.м.н., в.н.с. отдела клинической кардиологии.

Москва

Moscow

andorom@yandex.ruhttps://orcid.org/0000-0002-3138-054XКуликоваО. В.KulikovaO. V.

к.м.н., с.н.с. отдела клинической кардиологии.

Москва

Moscow

olgakulikova2014@mail.ruhttps://orcid.org/0000-0001-8846-8481КудрявцеваМ. М.KudryavtsevaM. M.

м.н.с. отдела клинической кардиологии.

Москва

Moscow

kudryavtseva6041995@yandex.ruhttps://orcid.org/0000-0002-1266-4926МершинаЕ. А.MershinaE. A.

к.м.н., зав. отделением рентгенодиагностики "Медицинский научно-образовательный центр МГУ им. М. В. Ломоносова", доцент кафедры лучевой диагностики, лучевой терапии и медицинской физики.

Москва

Moscow

elena_mershina@mail.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

д.м.н., профессор, академик РАН, директор.

Москва

Moscow

ODrapkina@gnicpm.ruФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава РоссииNational Medical Research Center for Therapy and Preventive MedicineФГБОУ ВО "Московский государственный университет им. М.В. Ломоносова"Lomonosov Moscow State University202307022024221238393839Copyright © Бурнашева Г.А., Мясников Р.П., Куликова О.В., Кудрявцева М.М., Мершина Е.А., Драпкина О.М., 20232023Бурнашева Г.А., Мясников Р.П., Куликова О.В., Кудрявцева М.М., Мершина Е.А., Драпкина О.М.Burnasheva G.A., Myasnikov R.P., Kulikova O.V., Kudryavtseva M.M., Mershina E.A., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3839

Гипертрофическая кардиомиопатия (ГКМП) на клеточном уровне характеризуется гипертрофией и дезорганизацией кардиомиоцитов, наличием участков фиброза миокарда. Ведущей причиной смерти при ГКМП остается внезапная сердечная смерть (ВСС). Несмотря на существующие шкалы оценки риска ВСС при ГКМП, по-прежнему, есть пациенты, у которых риск ВСС остается неопределенным, кроме того, случаи ВСС регистрируются и среди пациентов низкого риска. Из вышесказанного необходимость продолжать поиск новых маркеров для более точной оценки клинической ситуации. В настоящее время предполагается, что фиброз является субстратом потенциально опасных для жизни желудочковых аритмий. Несмотря на все более широкое использование магнитно-резонансной томографии сердца в диагностике фиброза миокарда и стратификации пациентов высокого риска ВСС, актуальным и перспективным направлением остается определение биомаркеров развития фиброза миокарда. В статье приведены результаты ряда исследований, доказывающих диагностическую значимость и взаимосвязь с риском развития жизнеугрожающих нарушений ритма сердца следующих маркеров: C-концевого пропептида проколлагена I типа, белков системы матриксных металлопротеиназ, тканевого ингибитора металлопротеиназы 1 типа, семейства микроРНК, растворимого супрессора туморогенности-2, галектина-3, апелина. Оценка данных биомаркеров может быть использована для улучшения стратификации риска пациентов с ГКМП.

Hypertrophic cardiomyopathy (HCM) at the cellular level is characterized by hypertrophy, cardiomyocyte disorganization and myocardial fibrosis areas. The leading death cause in HCM remains sudden cardiac death (SCD). Despite the existing risk scores for SCD in HCM, there are still patients with uncertain SCD risk. In addition, SCD cases are also recorded among low-risk patients. From the above, search for novel markers for a more accurate risk assessment should be continued. Fibrosis is currently suspected to be a substrate of potentially life-threatening ventricular arrhythmias. Despite the increasingly widespread use of cardiac magnetic resonance imaging in the diagnosis of myocardial fibrosis and stratification of patients at high SCD risk, the determination of myocardial fibrosis biomarkers remains a relevant and promising area. The article presents the results of studies proving the diagnostic significance and relationship with the risk of life-threatening cardiac arrhythmias of the following markers: C-propeptide of type I procollagen, matrix metalloproteinase proteins, tissue inhibitor of metalloproteinases 1, microRNA family, soluble suppression of tumorigenicity 2, galectin-3, apelin. Evaluation of these biomarkers can be used to improve risk stratification of patients with HCM.

гипертрофическая кардиомиопатиявнезапная смертьмаркеры фиброза миокардаhypertrophic cardiomyopathysudden deathmyocardial fibrosis markersReferencesГабрусенко С. А., Гудкова А. Я., Козиолова Н. А. и др. Клинические рекомендации по диагностике и лечению гипертрофической кардиомиопатии. Российский кардиологический журнал. 2021;26(5):4541. doi:10.15829/1560-4071-2021-4541.Gabrusenko SA, Gudkova AY, Koziolova NA, et al. 2020 Clinical Practice Guidelines for Hypertrophic Cardiomyopathy. Russian Journal of Cardiology. 2021;26(5):4541. (In Russ.) doi:10.15829/1560-4071-2021-4541.Olivotto I, Cecchi F, Poggesi C, et al. Developmental origins of hypertrophic cardiomyopathy phenotypes: A unifying hypothesis. Nat Rev Cardiol. 2009;6(4):317-21. doi:10.1038/nrcardio.2009.9.Olivotto I, Cecchi F, Poggesi C, et al. Developmental origins of hypertrophic cardiomyopathy phenotypes: A unifying hypothesis. Nat Rev Cardiol. 2009;6(4):317-21. doi:10.1038/nrcardio.2009.9.Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018;379(7):655-68. doi:10.1056/nejmra1710575.Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018;379(7):655-68. doi:10.1056/nejmra1710575.Kramer CM, Appelbaum E, Desai MY, et al. Hypertrophic Cardiomyopathy Registry. Am. Heart J. 2015;170(2):223-30. doi:10.1016/j.ahj.2015.05.013.Kramer CM, Appelbaum E, Desai MY, et al. Hypertrophic Cardiomyopathy Registry. Am. Heart J. 2015;170(2):223-30. doi:10.1016/j.ahj.2015.05.013.O’Hanlon R, Mohiaddin RH. Inherited cardiomyopathies. Magn Reson Imaging Congenit Hear Dis. 2012. pp. 211-229. doi:10.1007/978-1-4471-4267-6_13.O’Hanlon R, Mohiaddin RH. Inherited cardiomyopathies. Magn Reson Imaging Congenit Hear Dis. 2012. pp. 211-229. doi:10.1007/978-1-4471-4267-6_13.Kaski JP, Syrris P, Esteban MT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2(5):436-41. doi:10.1161/circgenetics.108.821314.Kaski JP, Syrris P, Esteban MT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2(5):436-41. doi:10.1161/circgenetics.108.821314.Габрусенко С. А., Селезнёв Д. М., Парфенова Е. В. и др. Роль мутаций в гене тяжелой цепи сердечного β-миозина в российской популяции больных с гипертрофической кардиомиопатией. Кардиология. 2005;45(4):15-20.Gabrusenko SA, Seleznev DM, Parfenova EV, et al. The role of mutation in cardiac beta-myosin heavy chain gene in population of patients. Kardiologiia. 2005;45(4):15-20. (In Russ.)Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83(6):630-8. doi:10.4065/83.6.630.Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83(6):630-8. doi:10.4065/83.6.630.Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045.Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045.Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;00:1-124. doi:10.1093/eurheartj/ehad194.Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;00:1-124. doi:10.1093/eurheartj/ehad194.Chute M, Aujla P, Jana S, et al. The non-fibrillar side of fibrosis: Contribution of the basement membrane, proteoglycans, and glycoproteins to myocardial fibrosis. J Cardiovasc Dev Dis. 2019;6(4). doi:10.3390/jcdd6040035.Chute M, Aujla P, Jana S, et al. The non-fibrillar side of fibrosis: Contribution of the basement membrane, proteoglycans, and glycoproteins to myocardial fibrosis. J Cardiovasc Dev Dis. 2019;6(4). doi:10.3390/jcdd6040035.Frangogiannis NG. Transforming growth factor–ß in tissue fibrosis. J Exp Med. 2020;217(3):1-16. doi:10.1084/jem.20190103.Frangogiannis NG. Transforming growth factor–ß in tissue fibrosis. J Exp Med. 2020;217(3):1-16. doi:10.1084/jem.20190103.Shirani J, Pick R, Roberts WC, et al. Morphology and Significance of the Left Ventricular Collagen Network in Young Patients With Hypertrophic Cardiomyopathy and Sudden Cardiac Death. JACC. 1999;35(1):1-9.Shirani J, Pick R, Roberts WC, et al. Morphology and Significance of the Left Ventricular Collagen Network in Young Patients With Hypertrophic Cardiomyopathy and Sudden Cardiac Death. JACC. 1999;35(1):1-9.Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: Accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013;6(5):587-96. doi:10.1016/j.jcmg.2012.09.018.Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: Accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013;6(5):587-96. doi:10.1016/j.jcmg.2012.09.018.Weissler-Snir A, Adler A, Williams L, et al. Prevention of sudden death in hypertrophic cardiomyopathy: Bridging the gaps in knowledge. Eur Heart J. 2017;38(22):1728-37. doi:10.1093/eurheartj/ehw268.Weissler-Snir A, Adler A, Williams L, et al. Prevention of sudden death in hypertrophic cardiomyopathy: Bridging the gaps in knowledge. Eur Heart J. 2017;38(22):1728-37. doi:10.1093/eurheartj/ehw268.Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54. doi:10.1016/j.jacc.2015.01.019.Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54. doi:10.1016/j.jacc.2015.01.019.Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: From bench to the clinics. J Cardiovasc Electrophysiol. 2008;19(1):104-10. doi:10.1111/j.1540-8167.2007.00965.x.Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: From bench to the clinics. J Cardiovasc Electrophysiol. 2008;19(1):104-10. doi:10.1111/j.1540-8167.2007.00965.x.McKenna W, Deanfield J, Faruqui A, et. al. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981;47(3):532-8. doi:10.1016/0002-9149(81)90535-X.McKenna W, Deanfield J, Faruqui A, et. al. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981;47(3):532-8. doi:10.1016/0002-9149(81)90535-X.Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-867l. doi:10.1093/eurheartj/ehv316.Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-867l. doi:10.1093/eurheartj/ehv316.Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation. 2020;142(3):217-29. doi:10.1161/CIRCULATIONAHA.120.047235.Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation. 2020;142(3):217-29. doi:10.1161/CIRCULATIONAHA.120.047235.Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientif. Circulation. 2015;132(22):e273-80. doi:10.1161/CIR.0000000000000239.Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientif. Circulation. 2015;132(22):e273-80. doi:10.1161/CIR.0000000000000239.Harmon KG, Asif IM, Maleszewski JJ, et al. Response to Letter Regarding Article, "incidence, cause, and comparative frequency of sudden cardiac death in national collegiate athletic association athletes: A decade in review". Circulation. 2016;133(12):e447. doi:10.1161/CIRCULATIONAHA.116.020661.Harmon KG, Asif IM, Maleszewski JJ, et al. Response to Letter Regarding Article, "incidence, cause, and comparative frequency of sudden cardiac death in national collegiate athletic association athletes: A decade in review". Circulation. 2016;133(12):e447. doi:10.1161/CIRCULATIONAHA.116.020661.Bagnall RD, Weintraub RG, Ingles J, et al. A Prospective Study of Sudden Cardiac Death among Children and Young Adults. N Engl J Med. 2016;374(25):2441-52. doi:10.1056/nejmoa1510687.Bagnall RD, Weintraub RG, Ingles J, et al. A Prospective Study of Sudden Cardiac Death among Children and Young Adults. N Engl J Med. 2016;374(25):2441-52. doi:10.1056/nejmoa1510687.Maron BJ, Rowin EJ, Casey SA, et al. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: Shaped by 50 years of clinical research and practice. JAMA Cardiol. 2016;1(1):98-105. doi:10.1001/jamacardio.2015.0354.Maron BJ, Rowin EJ, Casey SA, et al. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: Shaped by 50 years of clinical research and practice. JAMA Cardiol. 2016;1(1):98-105. doi:10.1001/jamacardio.2015.0354.Zamorano JL, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.Zamorano JL, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014;35(30): 2010-20. doi:10.1093/eurheartj/eht439.O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014;35(30): 2010-20. doi:10.1093/eurheartj/eht439.Kwon DH, Setser RM, Popović ZB, et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: A delayed contrast enhanced MRI study. Int J Cardiovasc Imaging. 2008;24(6):617-25. doi:10.1007/s10554-008-9292-6.Kwon DH, Setser RM, Popović ZB, et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: A delayed contrast enhanced MRI study. Int J Cardiovasc Imaging. 2008;24(6):617-25. doi:10.1007/s10554-008-9292-6.Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2008;51(14):1369-74. doi:10.1016/j.jacc.2007.11.071.Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2008;51(14):1369-74. doi:10.1016/j.jacc.2007.11.071.Monserrat L, Elliott PM, Gimeno JR, et. al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42(5):873-9. doi:10.1016/S0735-1097(03)00827-1.Monserrat L, Elliott PM, Gimeno JR, et. al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42(5):873-9. doi:10.1016/S0735-1097(03)00827-1.Adabag AS, Casey SA, Kuskowski MA, et. al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):697-704. doi:10.1016/j.jacc.2004.11.04.3.Adabag AS, Casey SA, Kuskowski MA, et. al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):697-704. doi:10.1016/j.jacc.2004.11.04.3.Prinz C, Schwarz M, Ilic I, et al. Myocardial Fibrosis Severity on Cardiac Magnetic Resonance Imaging Predicts Sustained Arrhythmic Events in Hypertrophic Cardiomyopathy. Can J Cardiol. 2013;29(3):358-63. doi:10.1016/j.cjca.2012.05.004.Prinz C, Schwarz M, Ilic I, et al. Myocardial Fibrosis Severity on Cardiac Magnetic Resonance Imaging Predicts Sustained Arrhythmic Events in Hypertrophic Cardiomyopathy. Can J Cardiol. 2013;29(3):358-63. doi:10.1016/j.cjca.2012.05.004.Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. J Cardiovasc Magn Reson. 2002;4(2):20310. doi:10.1081/JCMR-120003946.Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. J Cardiovasc Magn Reson. 2002;4(2):20310. doi:10.1081/JCMR-120003946.Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484-95. doi:10.1161/CIRCULATIONAHA.113.007094.Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484-95. doi:10.1161/CIRCULATIONAHA.113.007094.Weng Z, Yao J, Chan RH, et al. Prognostic Value of LGECMR in HCM: A Meta-Analysis. JACC Cardiovasc Imaging. 2016;9(12):1392-402. doi:10.1016/j.jcmg.2016.02.031.Weng Z, Yao J, Chan RH, et al. Prognostic Value of LGECMR in HCM: A Meta-Analysis. JACC Cardiovasc Imaging. 2016;9(12):1392-402. doi:10.1016/j.jcmg.2016.02.031.Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. J Am Coll Cardiol. 2018;72(8):85770. doi:10.1016/j.jacc.2018.05.060.Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. J Am Coll Cardiol. 2018;72(8):85770. doi:10.1016/j.jacc.2018.05.060.Liu J, Zhao S, Yu S, et al. Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy. Radiology. 2022;302(2):298-306. doi:10.1148/radiol.2021210914.Liu J, Zhao S, Yu S, et al. Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy. Radiology. 2022;302(2):298-306. doi:10.1148/radiol.2021210914.Каретникова В. Н., Кашталап В. В., Косарева С. Н. и др. Фиброз миокарда: современные аспекты проблемы. Терапевтический архив. 2017;89(1):88-93. doi:10.17116/terarkh201789188-93.Karetnikova VN, Kashtalap VV, Kosareva SN, et. al. Myocardial fibrosis: Current aspects of the problem. Terapevticheskii arkhiv. 2017;89(1):88-93. (In Russ.) doi:10.17116/terarkh201789188-93.Ding Y, Wang Y, Zhang W, et al. Roles of Biomarkers in Myocardial Fibrosis. Aging Dis. 2020;11(5):1157. doi:10.14336/ad.2020.0604.Ding Y, Wang Y, Zhang W, et al. Roles of Biomarkers in Myocardial Fibrosis. Aging Dis. 2020;11(5):1157. doi:10.14336/ad.2020.0604.Roldán V, Marín F, Gimeno JR, et al. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J. 2008;156(1):85-91. doi:10.1016/j.ahj.2008.01.035.Roldán V, Marín F, Gimeno JR, et al. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J. 2008;156(1):85-91. doi:10.1016/j.ahj.2008.01.035.Fang L, Ellims AH, Moore X, et al. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J Transl Med. 2015;13(1):1-12. doi:10.1186/s12967-015-0672-0.Fang L, Ellims AH, Moore X, et al. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J Transl Med. 2015;13(1):1-12. doi:10.1186/s12967-015-0672-0.Münch J, Avanesov M, Bannas P, et al. Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy. J Card Fail. 2016;22(10):845-50. doi:10.1016/j.cardfail.2016.03.010.Münch J, Avanesov M, Bannas P, et al. Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy. J Card Fail. 2016;22(10):845-50. doi:10.1016/j.cardfail.2016.03.010.Gawor M, Śpiewak M, Janas J, et al. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Kardiol Pol. 2017;75(10):997-1004. doi:10.5603/KP.a2017.0118.Gawor M, Śpiewak M, Janas J, et al. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Kardiol Pol. 2017;75(10):997-1004. doi:10.5603/KP.a2017.0118.Pchejetski D, Foussal C, Alfarano C, et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. 2012;33(18):2360-9. doi:10.1093/eurheartj/ehr389.Pchejetski D, Foussal C, Alfarano C, et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. 2012;33(18):2360-9. doi:10.1093/eurheartj/ehr389.Zhou Y, Yuan J, Wang Y, et al. Predictive values of apelin for myocardial fibrosis in hypertrophic cardiomyopathy. Int Heart J. 2019;60(3):648-55. doi:10.1536/ihj.18-598.Zhou Y, Yuan J, Wang Y, et al. Predictive values of apelin for myocardial fibrosis in hypertrophic cardiomyopathy. Int Heart J. 2019;60(3):648-55. doi:10.1536/ihj.18-598.Emet S, Dadashov M, Sonsoz MR, et al. Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Am J Med Sci. 2018;356(6):537-43. doi:10.1016/j.amjms.2018.08.013.Emet S, Dadashov M, Sonsoz MR, et al. Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Am J Med Sci. 2018;356(6):537-43. doi:10.1016/j.amjms.2018.08.013.Huang D, Chen Z, Wang J, et al. MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy. Biosci Rep. 2020;40(1):1-13. doi:10.1042/BSR20191234.Huang D, Chen Z, Wang J, et al. MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy. Biosci Rep. 2020;40(1):1-13. doi:10.1042/BSR20191234.Yang C, Qiao S, Song Y, et al. Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2019;43:107150. doi:10.1016/j.carpath.2019.107150.Yang C, Qiao S, Song Y, et al. Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2019;43:107150. doi:10.1016/j.carpath.2019.107150.Scolari FL, Faganello LS, Garbin HI, et. al. A systematic review of microRNAs in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2021;327:146-54. doi:10.1016/j.ijcard.2020.11.004.Scolari FL, Faganello LS, Garbin HI, et. al. A systematic review of microRNAs in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2021;327:146-54. doi:10.1016/j.ijcard.2020.11.004.Zaitsev VV, Gurshchenkov AV, Mitrofanova LB, et al. Clinical significance of different assessment methods of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Kardiologiia. 2020;60(3):44-50. doi:10.18087/cardio.2020.3.n561.Zaitsev VV, Gurshchenkov AV, Mitrofanova LB, et al. Clinical significance of different assessment methods of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Kardiologiia. 2020;60(3):44-50. doi:10.18087/cardio.2020.3.n561.Vullaganti S, Levine J, Raiker N, et al. Fibrosis in Hypertrophic Cardiomyopathy Patients With and Without Sarcomere Gene Mutations. Hear Lung Circ. 2021;30(10):1496-501. doi:10.1016/j.hlc.2021.04.008.Vullaganti S, Levine J, Raiker N, et al. Fibrosis in Hypertrophic Cardiomyopathy Patients With and Without Sarcomere Gene Mutations. Hear Lung Circ. 2021;30(10):1496-501. doi:10.1016/j.hlc.2021.04.008.

The authors declare that there are no conflicts of interest present.